For a post-menopausal woman with a pT1c node negative HER2 positive breast cancer, does ER status influence your choice of adjuvant paclitaxel/trastuzumab versus docetaxel/carboplatin/trastuzumab?

This is a patient with a 1.8cm node negative HER2 positive tumor that is grade 3, high Ki67, and ER positive.

Answer from: Medical Oncologist at Community Practice

Data from pivotal trials addressing adjuvant therapy options for HER2 positive cancers, like BCIRG 006 and APT, doesn't support treating ER positive, HER2 positive cancers any differently than ER negative, HER2 positive cancers.BCIRG 006 that showed TCH regimen to be as good as ACT-H (and superior t...

Comments

Medical Oncologist at San Mateo Medical Center
Would you consider the addition of Perjeta based o...

Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center
High Ki-67 are common in Her 2 Positive cancers an...

Please select the option that best describes you:

For a post-menopausal woman with a pT1c node negative HER2 positive breast cancer, does ER status influence your choice of adjuvant paclitaxel/trastuzumab versus docetaxel/carboplatin/trastuzumab?

Related Questions